CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc. reported first‑quarter 2026 results showing essentially flat revenue but higher losses as it invests in product development and clinical programs. Net revenue was $2,792 thousand, compared with $2,783 thousand a year earlier, while net loss widened to $7,033 thousand from $5,375 thousand.
Operating expenses rose to $8,422 thousand, driven mainly by research and development spending of $4,435 thousand as the company advances its CapsoCam Colon and AI initiatives. A March 2026 private placement added approximately $14,000 thousand in gross proceeds, lifting cash and cash equivalents to $17,933 thousand at March 31, 2026.
Despite the capital raise, management concluded that substantial doubt exists about CapsoVision’s ability to continue as a going concern within one year, given ongoing operating losses, negative operating cash flows of $6,066 thousand for the quarter, and the need for additional financing to meet growth and innovation objectives.
CapsoVision, Inc. reported first quarter 2026 revenue of $2.8 million, essentially unchanged from the prior year period, as a small decline in capsule volume was offset by a slightly higher average selling price. Gross margin fell to 48% from 54%, reflecting the impact of changes in U.S. trade policies and tariffs.
Operating expenses increased to $8.4 million, mainly from development work under a Canon Inc. agreement and clinical trials for the second-generation CapsoCam Colon, leading to a wider net loss of $7.0 million. Cash and cash equivalents rose to $17.9 million as of March 31, 2026, helped by completion of a $14 million private placement of equity on March 16, 2026. The company highlighted progress toward anticipated FDA clearance of its AI-assisted reading feature for CapsoCam Plus and ongoing pipeline programs in colon and pancreatic cancer diagnostics.
CapsoVision, Inc. ownership update: an amendment to a Schedule 13G/A reports that the Reporting Persons may be deemed to beneficially own an aggregate 5,100,867 shares of common stock as of March 26, 2026. The filing cites 49,838,211 shares outstanding as of March 25, 2026, producing reported percentages of 10.2% (Eliyahou Harari), 8.5% (Britt Harari), and 6.4% (Harari Family Trust). The schedule discloses direct ownership of 878,448 shares by Mr. Harari and indirect holdings through three trusts for which Mr. and Ms. Harari serve as trustees.
CapsoVision, Inc Head of Global Sales Douglas Patrick Atkinson exercised stock options to acquire a total of 107,357 shares of common stock on May 4–5, 2026. The options were exercised at prices of $0.2863, $0.3663 and $0.5661 per share, with the exercise prices and share counts reflecting a 1‑for‑3.33 reverse stock split completed in connection with the company’s initial public offering. Following these exercises, he directly holds 107,357 common shares and retains 18,769 stock options with a $0.5661 exercise price expiring on July 23, 2033. No open‑market sales were reported in this filing.
CapsoVision, Inc. has called its 2026 Annual Meeting of Stockholders for June 11, 2026, at 9:00 a.m. Pacific, to be held as a virtual-only meeting at www.virtualshareholdermeeting.com/CV2026. Holders of 49,849,728 common shares as of April 13, 2026 may vote.
Stockholders will vote on re-electing three Class I directors—Joanne Imperial, M.D., Wen‑Herng (Henry) King, and Michele Harari—for terms ending at the 2029 meeting, and on ratifying Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting FOR all nominees and FOR ratifying Baker Tilly.
CapsoVision, Inc. is registering for resale up to 2,867,089 shares of common stock that were issued in a private placement (the “PIPE Shares”) under the Securities Purchase Agreement dated March 16, 2026.
The registration is being made pursuant to the Registration Rights Agreement dated March 16, 2026 and the selling stockholders will receive all proceeds from any resales; the company will receive no resale proceeds but will pay registration expenses.
CapsoVision, Inc. has filed a resale registration covering up to 2,867,089 shares of common stock previously issued in a March 2026 private placement. These PIPE Shares may be sold over time by existing investors, while the company receives no sale proceeds but pays offering expenses.
CapsoVision is a commercial-stage medical technology company focused on capsule endoscopy for gastrointestinal diagnostics, including its FDA-cleared CapsoCam Plus small bowel capsule and a second-generation CapsoCam Colon device in development. Revenue from CapsoCam Plus grew from about $11.8 million in 2024 to $13.6 million in 2025, driven mainly by higher capsule volumes.
CapsoVision, Inc reports beneficial ownership by Shen Ching Hang of 6,400,527 shares, representing 12.84% of the class based on 49,840,000 shares outstanding. The filing shows 3,991,606 shares with sole voting and dispositive power and 2,408,921 shares with shared voting and dispositive power. The filing states Star One Global Capital Limited is the entity through which indirect ownership is held and the parties filed a Joint Filing Agreement.
CapsoVision, Inc. received an Amendment No. 1 filing on Schedule 13G/A reporting that the named reporting persons (CID Greater China Venture Capital Fund III, L.P.; CID Venture Capital General Partner III, Limited; Altenza International Limited; Ching Yi Chang; and Chih Cheng Chang) each hold 5 percent or less of the company's common stock as reflected on the cover responses. The filing lists organizational details, business addresses, citizenship, and voting/dispositive power entries showing 0 sole and shared voting and dispositive power in the visible rows. The filing is signed by Ching Yi Chang and Chih Cheng Chang with signature dates of 04/07/2026; the cover page date shown is 03/31/2026.